| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 01, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 23,230 | -- | 23,230 |
| Aug 23, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 5,941 | -- | 7,354 |
| Aug 23, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 1,231 | -- | 8,585 |
| Aug 23, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 101,918 | -- | 110,503 |
| Aug 23, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 2,433 | -- | 112,936 |
| Aug 23, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 254,275 | -- | -- |
| Aug 23, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 52,720 | -- | -- |
| Aug 23, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 4,362,062 | -- | -- |
| Aug 23, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 104,167 | -- | -- |
| Aug 21, 2018 |
Chief Scientific Officer
|
Chief Scientific Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 1,413 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.